Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | MAT2A | P31153 | 6/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9490480 | 0.85 | F11 (0.55) | NOS1DAOMAT2AF11GRIN2D | |
| SCHEMBL27885715 | 0.78 | METAP2 (0.52) | NOS1DYRK1AAHRALDH1A1 | |
| SCHEMBL1785835 | 0.78 | CA2 (0.45) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30774289 | 0.78 | DAO (0.50) | DAOKDM4EAKR1B1AHR | |
| SCHEMBL2619123 | 0.78 | DAO (0.50) | NOS1DAOKDM4EMEN1KMT2A | |
| SCHEMBL8622233 | 0.78 | DAO (0.50) | DAOKDM4EAKR1B1AHR | |
| SCHEMBL8016146 | 0.78 | MAPT (0.52) | KDM4EMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL30774337 | 0.78 | DAO (0.50) | NOS1DAOKDM4EMEN1KMT2A | |
| Chlorobenzene SCHEMBL27870295 | 0.75 | KDM4E (0.41) | DAOKDM4EMEN1CASP1KMT2A | |
| SCHEMBL25327113 | 0.75 | CYP2A6 (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2248806-B1 | Quinazoline derivatives as tyrosine kinase inhibitors | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2013-04-24 | — | — | EP | disclosed |
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
| US-5849861-A | Polyquinazolines and methods for their preparation | HITACHI CHEMICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5686560-A | TREATING A MONOMER WITH A BASE IN A DIPOLAR SOLVENT | HITACHI CHEMICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | NOS1 1182/4885DYRK1A 1976/4885DAO 2905/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | NOS1 1887/4885DYRK1A 1626/4885DAO 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.